Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials - 23/04/21
, Martina Rothenbühler, PhD a, George CM Siontis, MD, PhD a, David E. Kandzari, MD b, Juan F. Iglesias, MD c, Masahiko Asami, MD a, Thierry Lefèvre, MD d, Raffaele Piccolo, MD, PhD e, Jacques Koolen, MD f, Shigeru Saito, MD g, h, Ton Slagboom, MD i, Olivier Muller, MD j, Ron Waksman, MD k, Stephan Windecker, MD aAbstract |
Background |
Newest generation drug-eluting stents combine biodegradable polymers with ultrathin stent platforms in order to minimize vessel injury and inflammatory response. Evidence from randomized controlled trials suggested that differences in stent design translate into differences in clinical outcome. The aim of the present study was to evaluate the safety and efficacy of ultrathin strut, biodegradable polymer sirolimus eluting stents (BP SES) compared with thin strut, durable polymer everolimus-eluting stents (DP EES) among patients undergoing percutaneous coronary intervention (PCI).
Methods |
We pooled individual participant data from 5 randomized trials (NCT01356888, NCT01939249, NCT02389946, NCT01443104, NCT02579031) including a total of 5,780 patients, and performed a one-stage meta-analysis using a mixed effects Cox regression model.
Results |
At a median duration of follow-up of 739 days (interquartile range 365-1,806 days), target-lesion failure occurred in 337 (10.3%) and 304 (12.2%) patients treated with BP SES and DP EES (HR 0.86, 95%CI 0.71-1.06, P = .16). There were no significant differences between BP SES and DP EES with regards to cardiac death (111 (3.4%) vs 102 (4.1%); HR 1.05, 95%CI 0.80-1.37, P = .73), target-vessel myocardial infarction (136 (4.1%) vs 126 (5.0%), HR 0.79, 95%CI 0.62-1.01, P = .061), and clinically-driven target-lesion revascularization (163 (5.0%) vs 147 (5.9%); HR 0.94, 95%CI 0.75-1.18, P = .61). The effect was consistent across major subgroups. In a landmark analysis, there was no significant interaction between treatment effect and timing of events.
Conclusions |
In this patient-level meta-analysis of 5 randomized controlled trials, BP SES were associated with a similar risk of target-lesion failure compared with DP EES among patients undergoing PCI.
Study registration |
PROSPERO registry (CRD42018109098).
Le texte complet de cet article est disponible en PDF.Abbreviations : BP SES, DES, DP EES, HR, IPD, PCI, TLF
Plan
Vol 235
P. 140-148 - mai 2021 Retour au numéro
Article précédent
- Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study
- Joris R. de Groot, Christian T. Ruff, Sabina A. Murphy, Rose A. Hamershock, Jim T. Vehmeijer, Anton J.M. Oude Ophuis, Laura Grip, Hans Lanz, Michele F. Mercuri, Elliott M. Antman, Robert P. Giugliano
- Percutaneous coronary intervention in patients with stable coronary artery disease and left ventricular systolic dysfunction: insights from the VA CART program
- Todd J. Brophy, Theodore J. Warsavage, Annika L. Hebbe, Mary E. Plomondon, Stephen W. Waldo, Sunil V. Rao, Adam D. DeVore, J. Antonio Gutierrez, Rajesh V. Swaminathan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?